المؤلفون: Fishbein, Diana H., Michael, Larry, Guthrie, Charles, Carr, Christine, Raymer, James

المساهمون: National Institute of Environmental Health Sciences

المصدر: Frontiers in Psychology ; volume 10 ; ISSN 1664-1078

الإتاحة: https://doi.org/10.3389/fpsyg.2019.01263Test

المؤلفون: Lim, Joseph K, Liapakis, Ann Marie, Shiffman, Mitchell L, Lok, Anna S, Zeuzem, Stefan, Terrault, Norah A, Park, James S, Landis, Charles S, Hassan, Mohamed, Gallant, Joel, Kuo, Alexander, Pockros, Paul J, Vainorius, Monika, Akushevich, Lucy, Michael, Larry, Fried, Michael W, Nelson, David R, Ben-Ari, Ziv, Group, HCV-TARGET Study

المصدر: Clinical Gastroenterology and Hepatology, vol 16, iss 11

مصطلحات موضوعية: Biomedical and Clinical Sciences, Clinical Sciences, Clinical Trials and Supportive Activities, Chronic Liver Disease and Cirrhosis, Hepatitis, Emerging Infectious Diseases, Hepatitis - C, Digestive Diseases, Clinical Research, Infectious Diseases, Liver Disease, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Infection, Good Health and Well Being, Adolescent, Adult, Aged, 80 and over, Antiviral Agents, Benzimidazoles, Drug Therapy, Combination, Drug-Related Side Effects and Adverse Reactions, Europe, Female, Fluorenes, Genotype, Hepacivirus, Hepatitis C

الوقت: 1811 - 1819.e4

وصف الملف: application/pdf

العلاقة: qt0sg8z5mv; https://escholarship.org/uc/item/0sg8z5mvTest

الإتاحة: https://escholarship.org/uc/item/0sg8z5mvTest

المؤلفون: Evon, Donna M., Dong, Meichen, Reeve, Bryce B., Peter, Joy, Michael, Larry, Lok, Anna S., Nelson, David R., Stewart, Paul W.

مصطلحات موضوعية: sustained virological response, comparative effectiveness, direct acting antiviral, instrument, patient‐reported outcomes, survey, Oncology and Hematology, Health Sciences

وصف الملف: application/pdf

العلاقة: Evon, Donna M.; Dong, Meichen; Reeve, Bryce B.; Peter, Joy; Michael, Larry; Lok, Anna S.; Nelson, David R.; Stewart, Paul W. (2022). "Sustainable and equivalent improvements in symptoms and functional well‐being following viral cure from ledipasvir/sofosbuvir versus elbasvir/grazoprevir for chronic hepatitis C infection: Findings from the randomized PRIORITIZE trial." Journal of Viral Hepatitis (9): 795-806.; https://hdl.handle.net/2027.42/174829Test; Journal of Viral Hepatitis; Liu GF, Lu K, Mogg R, Mallick M, Mehrotra DV. Should baseline be a covariate or dependent variable in analyses of change from baseline in clinical trials? Stat Med. 2009; 28: 2509 ‐ 2530.; Gordon SC, Muir AJ, Lim JK, et al. Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV‐TARGET. J Hepatol. 2015; 62: 286 ‐ 293.; Kixmiller S, Sloan AP, Wadsworth S, et al. Experiences of an HCV Patient engagement group: a seven‐year journey. Res Involv Engagem. 2021; 7: 7.; Cella D, Riley W, Stone A, et al. The Patient‐Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self‐reported health outcome item banks: 2005–2008. J Clin Epidemiol. 2010; 63: 1179 ‐ 1194.; Reeve BB, Hays RD, Bjorner JB, et al. Psychometric evaluation and calibration of health‐related quality of life item banks: plans for the Patient‐Reported Outcomes Measurement Information System (PROMIS). Med Care 2007; 45: S22 ‐ S31.; NIH PROMIS® Reference Populations. [Internet]. https://www.healthmeasures.net/scoreTest‐and‐interpret/interpret‐scores/promis/reference‐populations. Accessed September 17, 2021.; Evon DM, Amador J, Stewart P, et al. Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy. Aliment Pharmacol Ther. 2018; 47: 1001 ‐ 1011.; Lee AC, Driban JB, Price LL, Harvey WF, Rodday AM, Wang C. Responsiveness and minimally important differences for 4 patient‐reported outcomes measurement information system short forms: Physical function, pain interference, depression, and anxiety in knee osteoarthritis. J Pain. 2017; 18: 1096 ‐ 1110.; Khanna D, Hays RD, Shreiner AB, et al. Responsiveness to change and minimally important differences of the patient‐reported outcomes measurement information system gastrointestinal symptoms scales. Dig Dis Sci. 2017; 62: 1186 ‐ 1192.; Amtmann D, Kim J, Chung H, Askew RL, Park R, Cook KF. Minimally important differences for patient reported outcomes measurement information system pain interference for individuals with back pain. J Pain Res. 2016; 9: 251 ‐ 255.; Kroenke K, Yu Z, Wu J, Kean J, Monahan PO. Operating characteristics of PROMIS four‐item depression and anxiety scales in primary care patients with chronic pain. Pain Med. 2014; 15: 1892 ‐ 1901.; Anderson RT, Baran RW, Dietz B, Kallwitz E, Erickson P, Revicki DA. Development and initial psychometric evaluation of the hepatitis C virus‐patient‐reported outcomes (HCV‐PRO) instrument. Qual Life Res. 2014; 23: 561 ‐ 570.; Anderson RT, Baran RW, Erickson P, Revicki DA, Dietz B, Gooch K. Psychometric evaluation of the hepatitis C virus patient‐reported outcomes (HCV‐PRO) instrument: validity, responsiveness, and identification of the minimally important difference in a phase 2 clinical trial. Qual Life Res. 2014; 23: 877 ‐ 886.; Lu K. On efficiency of constrained longitudinal data analysis versus longitudinal analysis of covariance. Biometrics. 2010; 66: 891 ‐ 896.; Liang K, Zeger S. Longitudinal data analysis of continuous and discrete responses for pre–post designs. Sankhyā Ind J Stat (Series B). 2000; 62: 134 ‐ 148.; Marcellin F, Roux P, Protopopescu C, Duracinsky M, Spire B, Carrieri MP. Patient‐reported outcomes with direct‐acting antivirals for the treatment of chronic hepatitis C: current knowledge and outstanding issues. Expert Rev Gastroenterol Hepatol. 2017; 11: 259 ‐ 268.; Evon DM, Kim HP, Edwards A, et al. "If I get cured, my whole quality of life will change": patients’ anticipated and actualized benefits following cure from chronic hepatitis C. Dig Dis Sci. 2021; 67: 100 ‐ 120.; Younossi ZM, Stepanova M, Afdhal N, et al. Improvement of health‐related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. J Hepatol. 2015; 63: 337 ‐ 345.; Younossi ZM, Stepanova M, Pol S, Bronowicki JP, Carrieri MP, Bourliere M. The impact of ledipasvir/sofosbuvir on patient‐reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study. Liver Int. 2016; 36: 42 ‐ 48.; Serper M, Evon DM, Amador J, et al. Patient‐reported outcomes 12 months after hepatitis C treatment with direct‐acting antivirals: results from the PROP UP study. Liver Int. 2021; 41: 692 ‐ 704.; Schulte B, Schmidt CS, Manthey J, et al. Clinical and patient‐reported outcomes of direct‐acting antivirals for the treatment of chronic hepatitis C among patients on opioid agonist treatment: a real‐world prospective cohort study. Open Forum Infect Dis. 2020; 7: ofaa317.; Fagundes RN, Ferreira L, Pace FHL. Health‐related quality of life and fatigue in patients with chronic hepatitis C with therapy with direct‐acting antivirals agents interferon‐free. PLoS One. 2020; 15: e0237005.; Karimi‐Sari H, Hosseini MA, Nikjoo N, Bagheri Baghdasht MS, Alavian SM. Patient‐reported outcomes of sleep, mood and quality of life after treatment of chronic hepatitis C infection using direct‐acting antiviral agents. Clin Microbiol Infect 2020; 26: 1093.e5‐.e8.; Ichikawa T, Miyaaki H, Miuma S, et al. Direct‐acting antivirals improved the quality of life, ameliorated disease‐related symptoms, and augmented muscle volume three years later in patients with hepatitis C virus. Intern Med. 2020; 59: 2653 ‐ 2660.; Goutzamanis S, Horyniak D, Doyle JS, Hellard M, Higgs P. Perceived physical health outcomes of direct‐acting antiviral treatment for hepatitis C: a qualitative study. Harm Reduct J. 2021; 18: 73.; O’Sullivan M, Jones AM, Gage H, et al. ITTREAT (Integrated Community Test ‐ Stage ‐ TREAT) Hepatitis C service for people who use drugs: Real‐world outcomes. Liver Int. 2020; 40: 1021 ‐ 1031.; Tsui JI, Williams EC, Green PK, Berry K, Su F, Ioannou GN. Alcohol use and hepatitis C virus treatment outcomes among patients receiving direct antiviral agents. Drug Alcohol Depend. 2016; 169: 101 ‐ 109.; Grebely J, Dalgard O, Conway B, et al. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open‐label, single‐arm, phase 4, multicentre trial. Lancet Gastroenterol Hepatol. 2018; 3: 153 ‐ 161.; Recommendations for testing, managing, and treating hepatitis C. January 2022. Accessed January 17, 2022. http://www.hcvguidelines.orgTest; Lang CA, Conrad S, Garrett L, et al. Symptom prevalence and clustering of symptoms in people living with chronic hepatitis C infection. J Pain Symptom Manage. 2006; 31: 335 ‐ 344.; Jacobson IM, Cacoub P, Dal Maso L, Harrison SA, Younossi ZM. Manifestations of chronic hepatitis C virus infection beyond the liver. Clin Gastroenterol Hepatol. 2010; 8: 1017 ‐ 1029.; Younossi Z, Park H, Henry L, Adeyemi A, Stepanova M. Extrahepatic manifestations of hepatitis C: a meta‐analysis of prevalence, quality of life, and economic burden. Gastroenterology. 2016; 150: 1599 ‐ 1608.; Kleefeld F, Heller S, Ingiliz P, et al. Interferon‐free therapy in hepatitis C virus (HCV) monoinfected and HCV/HIV coinfected patients: effect on cognitive function, fatigue, and mental health. J Neurovirol. 2018; 24: 557 ‐ 569.; McCarthy M, Ortega MR. Neurological complications of hepatitis C infection. Curr Neurol Neurosci Rep. 2012; 12: 642 ‐ 654.; Grover VP, Pavese N, Koh SB, et al. Cerebral microglial activation in patients with hepatitis C: in vivo evidence of neuroinflammation. J Viral Hepat. 2012; 19: e89 ‐ e96.; Burgel B, Friesland M, Koch A, et al. Hepatitis C virus enters human peripheral neuroblastoma cells – evidence for extra‐hepatic cells sustaining hepatitis C virus penetration. J Viral Hepat. 2011; 18: 562 ‐ 570.; Tassi A, Gitto S, Piras C, et al. Cognitive, neurological and psychiatric disorders occurring in hepatitis C virus infection. Minerva Med. 2021; 112: 238 ‐ 245.; Monaco S, Mariotto S, Ferrari S, et al. Hepatitis C virus‐associated neurocognitive and neuropsychiatric disorders: advances in 2015. World J Gastroenterol. 2015; 21: 11974 ‐ 11983.; Tagliapietra M, Monaco S. Neuroimaging findings in chronic hepatitis C virus infection: Correlation with neurocognitive and neuropsychiatric manifestations. Int J Mol Sci. 2020; 21: 2478.; Ghany MG, Morgan TR. Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases‐Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 2020; 71: 686 ‐ 721.; Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT‐450/r‐ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014; 370: 1594 ‐ 1603.; Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir‐Elbasvir combination therapy for treatment‐naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015; 163: 1 ‐ 13.; Younossi ZM, Stepanova M, Henry L, et al. Effects of sofosbuvir‐based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2014; 12: 1349 ‐ 1359.e13.; Evon DM, Sarkar S, Amador J, et al. Patient‐reported symptoms during and after direct‐acting antiviral therapies for chronic hepatitis C: The PROP UP study. J Hepatol. 2019; 71: 486 ‐ 497.; Sung JC, Bosh C, Wyatt B, et al. Hepatitis C cure improved patient‐reported outcomes in patients with and without liver fibrosis in a prospective study at a large urban medical center. J Viral Hepat. 2020; 27: 350 ‐ 359.; Sulkowski MS, Moon J, Sherman K, et al. A pragmatic, randomized controlled trial of oral antivirals for the treatment of chronic hepatitis C: the prioritize study. Hepatology. 2021; 74: 2952 ‐ 2964.; Evon DM, Golin CE, Stoica T, et al. What’s important to the patient? Informational needs of patients making decisions about hepatitis C treatment. Patient. 2017; 10: 335 ‐ 344.

الإتاحة: https://doi.org/10.1111/jvh.13716Test
https://hdl.handle.net/2027.42/174829Test

المؤلفون: Sulkowski, Mark S., Moon, Juhi S., Sherman, Kenneth E., Morelli, Giuseppe, Darling, Jama M., Muir, Andrew J., Khalili, Mandana, Fishbein, Dawn A., Hinestrosa, Federico, Shiffman, Mitchell L., Di Bisceglie, Adrian, Rajender Reddy, K., Pearlman, Brian, Lok, Anna S., Fried, Michael W., Stewart, Paul W., Peter, Joy, Wadsworth, Summer, Kixmiller, Scott, Sloan, Anquenette, Vainorius, Monika, Horne, Patrick M., Michael, Larry, Dong, Meichen, Evon, Donna M., Segal, Jodi B., Nelson, David R.

مصطلحات موضوعية: Internal Medicine and Specialties, Health Sciences

وصف الملف: application/pdf

العلاقة: Sulkowski, Mark S.; Moon, Juhi S.; Sherman, Kenneth E.; Morelli, Giuseppe; Darling, Jama M.; Muir, Andrew J.; Khalili, Mandana; Fishbein, Dawn A.; Hinestrosa, Federico; Shiffman, Mitchell L.; Di Bisceglie, Adrian; Rajender Reddy, K.; Pearlman, Brian; Lok, Anna S.; Fried, Michael W.; Stewart, Paul W.; Peter, Joy; Wadsworth, Summer; Kixmiller, Scott; Sloan, Anquenette; Vainorius, Monika; Horne, Patrick M.; Michael, Larry; Dong, Meichen; Evon, Donna M.; Segal, Jodi B.; Nelson, David R. (2021). "A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study." Hepatology (6): 2952-2964.; https://hdl.handle.net/2027.42/170968Test; Hepatology; Hofmeister MG, Rosenthal EM, Barker LK, Rosenberg ES, Barranco MA, Hall EW, et al. Estimating prevalence of hepatitis C virus infection in the United States, 2013‐2016. Hepatology 2019; 69: 1020 ‐ 1031.; Dang H, Yeo YH, Yasuda S, Huang CF, Iio E, Landis C, et al. Cure with interferon free DAA is associated with increased survival in patients with HCV related HCC from both east and west. Hepatology 2020; 71: 1910 ‐ 1922.; Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2015; 2017: 161 ‐ 176.; Evon DM, Sarkar S, Amador J, Lok AS, Sterling RK, Stewart PW, et al. Patient‐reported symptoms during and after direct‐acting antiviral therapies for chronic hepatitis C: the PROP UP study. J Hepatol 2019; 71: 486 ‐ 497.; US Food and Drug Administration. FDA warns about rare occurrence of serious liver injury with use of hepatitis C medicines Mavyret, Zepatier, and Vosevi in some patients with advanced liver disease. FDA Drug Safety Communication. https://www.fda.gov/drugs/drugTest‐safety‐and‐availability/fda‐warns‐about‐rare‐occurrence‐serious‐liver‐injury‐use‐hepatitis‐c‐medicines‐mavyret‐zepatier‐and. Published August 28, 2019. Accessed August 2, 2020.; Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, et al. Grazoprevir‐elbasvir combination therapy for treatment‐naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 2015; 163: 1 ‐ 13.; O’Brien TR, Lang Kuhs KA, Pfeiffer RM. Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C. Open Forum Infect Dis 2014; 1: ofu110.; Fox DS, McGinnis JJ, Tonnu‐Mihara IQ, McCombs JS. Comparative treatment effectiveness of direct acting antiviral regimens for hepatitis C: data from the Veterans Administration. J Gastroenterol Hepatol 2017; 32: 1136 ‐ 1142.; Zeuzem S, Mizokami M, Pianko S, Mangia A, Han KH, Martin R, et al. NS5A resistance‐associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome. J Hepatol 2017; 66: 910 ‐ 918.; US Department of Health and Human Services. Viral hepatitis national strategic plan for the United States: A roadmap to elimination (2021‐2025). Washington, DC; 2020.; Wilder J, Saraswathula A, Hasselblad V, Muir A. A systematic review of race and ethnicity in hepatitis C clinical trial enrollment. J Natl Med Assoc 2016; 108: 24 ‐ 29.; Segal JB, PRIORITIZE HCV Study Group. Formulary restrictions may impact enrollment in pragmatic trials and limit generalizability of findings to vulnerable populations. Clin Trials 2020; 17: 729 ‐ 731.; Lu K. On efficiency of constrained longitudinal data analysis versus longitudinal analysis of covariance. Biometrics 2010; 66: 891 ‐ 896.; Firth D. Bias reduction of maximum likelihood estimates. Biometrika 1993; 80: 27 ‐ 38.; White IR, Horton NJ, Carpenter J, Pocock SJ. Strategy for intention to treat analysis in randomized trials with missing outcome data. BMJ 2011; 342: d40.; International Committee of Medical Journal Editors. Recommendations for the conduct, reporting, editing and publication of scholarly work in medical journals. http://www.icmje.org/icmjeTest‐recommendations.pdf. Published December 2019. Accessed July 9, 2020.; Wasserstein RL, Schirm AL, Lazar NA. Moving to a world beyond “ p < 0.05.” Am Stat 2019; 73 ( Suppl. 1 ): 1 ‐ 19.; Wasserstein RL, Lazar NA. The ASA statement on p ‐values: context, process, and purpose. Am Stat 2016; 70: 129 ‐ 133.; It’s time to talk about ditching statistical significance. Nature 2019; 567: 283.; Amrhein V, Greenland S, McShane B. Scientists rise up against statistical significance. Nature 2019; 567: 305 ‐ 307.; Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. BMJ 2010; 340: c332.; Voils CI, Maciejewski ML, Hoyle RH, Reeve BB, Gallagher P, Bryson CL, et al. Initial validation of a self‐report measure of the extent of and reasons for medication nonadherence. Med Care 2012; 50: 1013 ‐ 1019.; Voils CI, King HA, Thorpe CT, Blalock DV, Kronish IM, Reeve BB, et al. Content validity and reliability of a self‐report measure of medication nonadherence in hepatitis C treatment. Dig Dis Sci 2019; 64: 2784 ‐ 2797.; Anderson RT, Baran RW, Dietz B, Kallwitz E, Erickson P, Revicki DA. Development and initial psychometric evaluation of the hepatitis C virus‐patient‐reported outcomes (HCV‐PRO) instrument. Qual Life Res 2014; 23: 561 ‐ 570.; Spiegel BM, Hays RD, Bolus R, Melmed GY, Chang L, Whitman C, et al. Development of the NIH Patient‐Reported Outcomes Measurement Information System (PROMIS) gastrointestinal symptom scales. Am J Gastroenterol 2014; 109: 1804 ‐ 1814. Erratum in: Am J Gastroenterol 2015;110:608.; Reeve BB, Hays RD, Bjorner JB, Cook KF, Crane PK, Teresi JA, et al. Psychometric evaluation and calibration of health‐related quality of life item banks: plans for the Patient‐Reported Outcomes Measurement Information System (PROMIS). Med Care 2007; 45 ( 5 Suppl. 1 ): S22 ‐ S31.; Cella D, Riley W, Stone A, Rothrock N, Reeve B, Yount S, et al. The Patient‐Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self‐reported health outcome item banks: 2005‐2008. J Clin Epidemiol 2010; 63: 1179 ‐ 1194.; Bjorner JB, Kosinski M, Ware JE Jr. Using item response theory to calibrate the Headache Impact Test (HIT™) to the metric of traditional headache scales. Qual Life Res 2003; 12: 981 ‐ 100.; Kosinski M, Bayliss MS, Bjorner JB, Ware JE Jr, Garber WH, Batenhorst A, et al. A six‐item short‐form survey for measuring headache impact: the HIT‐6. Qual Life Res 2003; 12: 963 ‐ 974.; Mishra P, Florian J, Peter J, Vainorius M, Fried MW, Nelson DR, et al. Public–private partnership: targeting real‐world data for hepatitis C direct‐acting antivirals. Gastroenterology 2017; 153: 626 ‐ 631.; AASLD/IDSA HCV Guidance Panel Recommendations for testing, managing, and treating hepatitis C website. Published 2017. Accessed June 13, 2017. http://hcvguidelines.orgTest

الإتاحة: https://doi.org/10.1002/hep.32053Test
https://hdl.handle.net/2027.42/170968Test

المؤلفون: Fanto, Michael Larry

المصدر: Theses

مصطلحات موضوعية: Aluminum nitride, Integrated photonics, Nonlinear optics, Photon, Quantum, Ultrawide bandgap

وصف الملف: application/pdf

العلاقة: https://scholarworks.rit.edu/theses/10349Test; https://scholarworks.rit.edu/context/theses/article/11503/viewcontent/MFantoDissertation4_1_2020.pdfTest

الإتاحة: https://scholarworks.rit.edu/theses/10349Test
https://scholarworks.rit.edu/context/theses/article/11503/viewcontent/MFantoDissertation4_1_2020.pdfTest

المؤلفون: Raymer, James, Michael, Larry, Studabaker, William, Olsen, Geary, Sloan, Carol, Wilcosky, Timothy, Walmer, David

المصدر: Reproductive Toxicology, 33(4)

مصطلحات موضوعية: Humans, Environmental Pollutants, Chromatography, High Pressure Liquid, Cross-Sectional Studies, Caprylates, Environmental Exposure, Fluorocarbons, Semen, Male, Luteinizing Hormone, Alkanesulfonic Acids, Follicle Stimulating Hormone, North Carolina

العلاقة: https://doi.org/10.17615/793w-sb58Test; https://cdr.lib.unc.edu/downloads/n296x712f?file=thumbnailTest; https://cdr.lib.unc.edu/downloads/n296x712fTest

الإتاحة: https://doi.org/10.17615/793w-sb58Test
https://cdr.lib.unc.edu/downloads/n296x712f?file=thumbnailTest
https://cdr.lib.unc.edu/downloads/n296x712fTest

المؤلفون: Bird, Michael Larry

المصدر: Theological Research Exchange Network (TREN)

مصطلحات موضوعية: Marriage counseling, pastoral counseling

وصف الملف: application/pdf

العلاقة: https://digitalshowcase.oru.edu/tren/1030Test; https://digitalshowcase.oru.edu/cgi/viewcontent.cgi?article=2420&context=trenTest

الإتاحة: https://digitalshowcase.oru.edu/tren/1030Test
https://digitalshowcase.oru.edu/cgi/viewcontent.cgi?article=2420&context=trenTest

المؤلفون: Davis, Michael Larry

المساهمون: Wilder, Michael S., Parker, Shane W.

مصطلحات موضوعية: Leadership--Religious aspects--Christianity, Business--Religious aspects--Christianity, relig

العلاقة: http://hdl.handle.net/10392/4856Test

الإتاحة: http://hdl.handle.net/10392/4856Test

المؤلفون: Davis, Michael Larry

المساهمون: Wilder, Michael S., Parker, Shane W.

مصطلحات موضوعية: Leadership--Religious aspects--Christianity, Business--Religious aspects--Christianity

وصف الملف: application/pdf

العلاقة: http://hdl.handle.net/10392/4856Test

الإتاحة: http://hdl.handle.net/10392/4856Test

المؤلفون: ZWEIDINGER, RUTH A., COOPER, STEPHEN D., ERICKSON, MITCHELL D., MICHAEL, LARRY C., PELLIZZARI, EDO D.

المصدر: ACS Symposium Series ; Monitoring Toxic Substances ; page 217-231 ; ISSN 0097-6156 1947-5918 ; ISBN 9780841204805 9780841206175

الإتاحة: https://doi.org/10.1021/bk-1979-0094.ch013Test